Federal Register of Legislation - Australian Government

Primary content

No. 51 of 2022 Determinations/Veterans' Entitlements as made
This instrument amends the Statement of Principles concerning hypogonadism (Reasonable Hypothesis) (No. 73 of 2021).
Administered by: Veterans' Affairs
Registered 02 May 2022
Table of contents.

RMA-Red

 

Amendment Statement of Principles

concerning

HYPOGONADISM
(Reasonable Hypothesis)

(No. 51 of 2022)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

 

Dated      29 April 2022

 

 

 

 

 

The Common Seal of the
Repatriation Medical Authority
was affixed to this instrument
at the direction of:

 

 

 

Professor Terence Campbell AM

Chairperson

 

  

Contents

1          Name........................................................................................................................................... 3

2          Commencement........................................................................................................................ 3

3          Authority..................................................................................................................................... 3

4          Amendment............................................................................................................................... 3

 

 


 

1               Name

This is the Amendment Statement of Principles concerning hypogonadism (Reasonable Hypothesis) (No. 51 of 2022).

2               Commencement

This instrument commences on 30 May 2022.

3               Authority

This instrument is made under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

4               Amendment

The Statement of Principles concerning hypogonadism (Reasonable Hypothesis) (No. 73 of 2021) (Federal Register of Legislation No. F2021L00619) is amended in the following manner:

 

Section

Amendment

Schedule 1 – Dictionary

Replace the existing definition of "immune checkpoint inhibitor" with the following:

immune checkpoint inhibitor means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.